Understanding the role of these transporters in the clearance of new molecular entities (NME) is normally performed in-vitro at the early stages of drug development.
It is well known that food intake changes luminal conditions (e.g. pH, motility, microbiota,…) in the stomach and the small intestine, modifying drugs bioavailability. Food-drug interactions are one of the major challenges for oral-administered drugs, even more so if considering the growing use of food supplements and functional foods.
Specialized manufacturer of in vitro kits indicated to evaluate pharmacological relevant efflux and uptake receptors for TDI assays.
Transmembrane efflux receptors, Pgp, MRP1 and BCRP has shown a relevant effect in the chemoterapy resistance.
PreadyPort BCRP is a in vitro system based on transfected MDCKII cells overexpressing the BCRP transporter.